MA32473B1 - Derivatives 5 - (4 - methanesulfonyl - phenyl) - thiazole for the treatment of acute and chronic inflammatory diseases - Google Patents

Derivatives 5 - (4 - methanesulfonyl - phenyl) - thiazole for the treatment of acute and chronic inflammatory diseases

Info

Publication number
MA32473B1
MA32473B1 MA33516A MA33516A MA32473B1 MA 32473 B1 MA32473 B1 MA 32473B1 MA 33516 A MA33516 A MA 33516A MA 33516 A MA33516 A MA 33516A MA 32473 B1 MA32473 B1 MA 32473B1
Authority
MA
Morocco
Prior art keywords
acute
treatment
chronic inflammatory
methanesulfonyl
thiazole
Prior art date
Application number
MA33516A
Other languages
Arabic (ar)
French (fr)
Inventor
Royo Victor Rubio
La Hera Martínez Antonio De
De Mon Soto Melchor Álvarez
Muñoz Ana Muñoz
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08380177A external-priority patent/EP2135864A1/en
Priority claimed from US12/139,661 external-priority patent/US7781594B2/en
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MA32473B1 publication Critical patent/MA32473B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

L'invention porte sur l'utilisation d'un composé de formule (i) ou d'un sel, d'un promédicament et/ou d'un solvate pharmaceutiquement acceptables correspondants, dans la préparation d'un médicament pour le traitement d'une maladie inflammatoire aiguë ou chronique, par l'inhibition de la production d'au moins une cytokine pro-inflammatoire choisie parmi tnf-alpha et ifn-gamma, ou par immunomodulation de la chimiokine il-8 et/ou de la cytokine régulatrice il-10. L'invention porte également sur de nouveaux composés de formule (i') ou sur un sel, un promédicament et/ou un solvate pharmaceutiquement acceptables correspondants, ainsi que sur une composition pharmaceutique renfermant lesdits composés.The invention relates to the use of a compound of formula (i) or a corresponding pharmaceutically acceptable salt, prodrug and / or solvate, in the preparation of a medicament for the treatment of an acute or chronic inflammatory disease, by inhibiting the production of at least one pro-inflammatory cytokine selected from tnf-alpha and ifn-gamma, or by immunomodulation of the chemokine il-8 and / or the regulatory cytokine il -10. The invention also relates to novel compounds of formula (i ') or to a corresponding pharmaceutically acceptable salt, prodrug and / or solvate, as well as to a pharmaceutical composition comprising said compounds.

MA33516A 2008-06-16 2011-01-13 Derivatives 5 - (4 - methanesulfonyl - phenyl) - thiazole for the treatment of acute and chronic inflammatory diseases MA32473B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380177A EP2135864A1 (en) 2008-06-16 2008-06-16 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
US12/139,661 US7781594B2 (en) 2008-06-16 2008-06-16 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases
PCT/EP2009/057324 WO2009153226A1 (en) 2008-06-16 2009-06-15 5-(4-methanesulfonyl-phenyl)-thiazole derivatives for the treatment of acute and chronic inflammatory diseases

Publications (1)

Publication Number Publication Date
MA32473B1 true MA32473B1 (en) 2011-07-03

Family

ID=43414178

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33516A MA32473B1 (en) 2008-06-16 2011-01-13 Derivatives 5 - (4 - methanesulfonyl - phenyl) - thiazole for the treatment of acute and chronic inflammatory diseases

Country Status (19)

Country Link
EP (1) EP2313382A1 (en)
JP (1) JP2011524352A (en)
KR (1) KR20110022679A (en)
CN (1) CN102083806A (en)
AR (1) AR072113A1 (en)
AU (1) AU2009259451B2 (en)
BR (1) BRPI0915325A2 (en)
CA (1) CA2728139A1 (en)
CO (1) CO6331429A2 (en)
IL (1) IL209801A0 (en)
MA (1) MA32473B1 (en)
MX (1) MX2010013978A (en)
NZ (1) NZ589894A (en)
RU (1) RU2495031C2 (en)
SA (1) SA109300384B1 (en)
TW (1) TWI403506B (en)
UY (1) UY31896A (en)
WO (1) WO2009153226A1 (en)
ZA (1) ZA201008877B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961695B1 (en) * 2010-06-29 2012-07-06 Galderma Res & Dev USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
RU2502513C2 (en) * 2012-01-11 2013-12-27 Государственное бюджетное учреждение здравоохранения Свердловской области "Свердловский областной клинический психоневрологический госпиталь для ветеранов войн" (ГБУЗ СО "СОКП Госпиталь для ветеранов войн") Method of treating patients with multiple organ pathology using ozone therapy
MX2020005360A (en) * 2017-11-23 2020-08-13 Immunic Ag Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases.
KR102076936B1 (en) * 2019-08-12 2020-02-13 연세대학교 산학협력단 Composition including thiazole or salt thereof as active ingredients for preventing or treating allergic disease or atopic dermatitis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2877508B2 (en) * 1989-02-08 1999-03-31 アボツト・ラボラトリーズ 4-Hydroxythiazole as 5-lipoxygenase inhibitor
WO1996003392A1 (en) * 1994-07-27 1996-02-08 G.D. Searle & Co. Substituted thiazoles for the treatment of inflammation
ES2247604T3 (en) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. COMPOSITIONS THAT INCLUDE A CYCLLOXYGENASA-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR.
AU7559200A (en) * 1999-10-12 2001-04-23 Japan Tobacco Inc. Hypertriglyceridemia remedies and antiobestics
CA2451981C (en) * 2001-08-13 2012-02-21 Janssen Pharmaceutica N.V. 2,4,5-trisubstituted thiazolyl derivatives and their antiinflammatory activity
US20050026902A1 (en) * 2003-01-31 2005-02-03 Timothy Maziasz Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents

Also Published As

Publication number Publication date
WO2009153226A1 (en) 2009-12-23
NZ589894A (en) 2011-08-26
SA109300384B1 (en) 2013-04-20
MX2010013978A (en) 2011-03-29
CA2728139A1 (en) 2009-12-23
TWI403506B (en) 2013-08-01
IL209801A0 (en) 2011-02-28
AR072113A1 (en) 2010-08-04
KR20110022679A (en) 2011-03-07
JP2011524352A (en) 2011-09-01
TW201010988A (en) 2010-03-16
RU2011101439A (en) 2012-07-27
AU2009259451A1 (en) 2009-12-23
CN102083806A (en) 2011-06-01
UY31896A (en) 2010-01-29
BRPI0915325A2 (en) 2015-10-27
CO6331429A2 (en) 2011-10-20
EP2313382A1 (en) 2011-04-27
ZA201008877B (en) 2012-02-29
RU2495031C2 (en) 2013-10-10
AU2009259451B2 (en) 2013-03-14

Similar Documents

Publication Publication Date Title
MA32231B1 (en) Organic compounds
MA38323B1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
MA33745B1 (en) Alternative pepperdines that increase the activity of p53 and the use of their compounds
MA29335B1 (en) N- (N-SULFONYLAMINOMETHYL) CYCLOPROPANECARBOXAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF PAIN
EA200601350A1 (en) NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND THEIR PHARMACEUTICAL APPLICATIONS
EA200900178A1 (en) Condensed Heterocyclic Derivatives and Their Application
UA92746C2 (en) Thiazole compounds and methods of use
MA35804B1 (en) Modulation of the expression of the hepatitis b virus (vhb)
MX2024002425A (en) Substituted tricyclic compounds as parp inhibitors and use thereof.
BRPI0810641A2 (en) "pharmaceutical compounds".
ATE517882T1 (en) QUINOLINE DERIVATIVES
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MA34308B1 (en) SUBSTITUTED TRIAZOLOPYRIDINES
WO2009039397A3 (en) Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer
MA38315B1 (en) Heterocycle-substituted tetracyclic compounds and methods for their use in the treatment of viral diseases
MX2010001020A (en) Organic compounds.
MA32108B1 (en) Indendazole derivatives
MA32473B1 (en) Derivatives 5 - (4 - methanesulfonyl - phenyl) - thiazole for the treatment of acute and chronic inflammatory diseases
MA33563B1 (en) 5- (3,4-dichlorophenyl) n (2-hydroxyl-cyclohexyl) -6 (2,2,2-trichloroetoxy) nectanamide and salts used as an agent for raising HDL cholesterol
MX2008016358A (en) Thiazolyl urea derivatives as phosphatidylinositol 3-kinase inhibitors.
MA30540B1 (en) QUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS OF THESE DERIVATIVES.
MX2023012039A (en) Substituted fused bicyclic compounds as parp inhibitors and the use thereof.
EA200800071A1 (en) DERIVATIVES OF BENZOFURANILA AS AN INHIBITORS OF 5-НТ6-RECEPTOR
MX2020008523A (en) Compound having s1p5 receptor agonist activity.
MA32128B1 (en) An association between thiazolium bis salt and artemisinin or one of its derivatives for the treatment of acute malaria